Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: Results at 1 year of an open-labelled prospective study

Antiviral Therapy

Volumn 14, Issue 4, 2009, Pages 585-590

  Ko, Soon Young ^a   Kwon, So Young ^a   Choe, Won Hyeok ^a   Kim, Byung Kook ^a   Kim, Kyun Hwan ^a   Lee, Chang Hong ^a  

^a Konkuk University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; CLEVUDINE; DNA POLYMERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; 2'-FLUORO-5-METHYLARABINOSYLURACIL; ANTIVIRUS AGENT; DRUG DERIVATIVE; HEPATITIS B ANTIGEN; URACIL ARABINOSIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE EXACERBATION; DNA DETERMINATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LONG TERM CARE; MALE; MONOTHERAPY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REBOUND; SEROCONVERSION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS MUTATION; ANTIVIRAL RESISTANCE; BLOOD; LONGITUDINAL STUDY;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE;

EID: 68549097944     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis 2004; 24 Suppl. 1:17-21.
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
3. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007 45:1172-1178.
4. Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy vira ppression. Hepatology 2007; 46:1041-1048.
5. Lee HS, Chung YH, Lee K, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2006; 43:982-988.
6. Lim SG, Leung N, Hann HW, et al. Clinical trial: a Phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther 2008; 27:1282-1292.
7. Marcellin P, Mommeja-Marin H, Sacks SL, et al. A Phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004; 40:140-148.
8. Chu CK, Ma T, Shanmuganathan K, et al. Use of 2∓-fluoro- 5-methyl-beta-L-arabinotranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus Antimicrob Agents Chemother 1995; 39:979-981.
9. Yao GQ, Liu SH, Chou E, Kukhanova, Chu CK, Cheng YC. Inhibition of Epstein-Barr virus replication by a novel 1.-nucleoside, 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil. Biochem Pbarmacol 1996; 51:941-947.
10. Asselah T, Lada O, Moucari R, Marcellin P. Clevudine: a promising therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2008; 17:1963-1974.
11. Hong SP, Kim NK, Hwang SG, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004; 40:837-844.
12. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE, IV. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10:625-633.
13. Mauss S, Wedemeyer H. Treatment of chronic hepatitis B and the implications of viral resistance to therapy. Expert Rev Anti Infect Ther 2008; 6:191-199.
14. Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatits B: results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47:447-454.
15. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudiiie in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588.
16. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
17. Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivuduie in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123:1831-1838.
18. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816.
19. Fu L, Liu SH, Cheng YC. Sensitivity Of L-(-)2′,3′-dideoxythracytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem Pharmacol 1999; 57:1351-1359.